AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

Recruitingn/aAges 18 Years - anyAllIRCCS San Raffaele
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases. 840 patients with Central Nervous System neurological diseases (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine/headache) and 210 age-matched healthy controls will undergo OCT examination at baseline and at 6, 12, 18, and 24 months of follow-up at IRCCS San Raffaele Hospital, Milan, Italy. OCT is a non-invasive, rapid, and reproducible technique that automatically measures the thickness of individual retinal layers. Retinal layer thicknesses and their longitudinal changes will be correlated with established clinical scales, neuroimaging, and biological markers used in routine neurological practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria for neurological patients: 1. Diagnosis of a Central Nervous System neurological disease (inflammatory diseases such as Multiple Sclerosis; neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease; migraine/headache) according to currently accepted diagnostic criteria for each condition. 2. Age greater than 18 years. 3. Signed informed consent to study participation. 4. Willingness and ability to undergo all study visits and procedures. Inclusion Criteria for healthy controls: 1. Absence of neurological disease. 2. Age greater than 18 years. 3. Signed informed consent to study participation. 4. Willingness and ability to undergo all study visits and procedures. Exclusion Criteria for neurological patients: 1. Refusal to participate or withdrawal of informed consent. 2. Known or confirmed ocular pathology identified during examination (ophthalmological evaluation may be requested at the investigators' discretion). 3. Inability to understand instructions given by investigators. 4. Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study. 5. For specific imaging modes using clearly visible light sources (MultiColor, FA, BAF): diagnosis of epilepsy or history of previous epileptic seizures. Exclusion Criteria for healthy controls: 1. Refusal to participate or withdrawal of informed consent. 2. Known or confirmed ocular pathology identified during examination. 3. Inability to understand instructions given by investigators. 4. Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study.
๐Ÿ’Š

What it tests

  • Optical Coherence Tomography (OCT) - Heidelberg SPECTRALIS HRA+OCT
๐Ÿ“

Where

1 site
IRCCS Ospedale San Raffaele - Neurology and Neurophysiology Unit
Milan, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy